Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network

Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab. This retrospective study is the first to describe real-world treatment patterns and changes in hematologic PNH-monitoring laboratory tests among...

Descripción completa

Detalles Bibliográficos
Autores principales: Fishman, Jesse, Kuranz, Seth, Yeh, Michael M., Brzozowski, Kaylen, Chen, Herman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123631/
https://www.ncbi.nlm.nih.gov/pubmed/37092521
http://dx.doi.org/10.3390/hematolrep15020027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123631/
https://www.ncbi.nlm.nih.gov/pubmed/37092521
http://dx.doi.org/10.3390/hematolrep15020027

Ejemplares similares